Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics,… bypharmanewsdailySeptember 19, 2020
